New hope for rare bone disease: phase 3 trial of ALXN1850 underway

NCT ID NCT06079281

Ongoing Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 17, 2026 · Updated 24 times

Summary

This study tests a new medicine called ALXN1850 for people aged 12 and older with hypophosphatasia (HPP), a rare bone disease. Participants receive either the drug or a placebo to see if it improves walking, strength, and daily function. The trial involves 124 people across multiple centers and is currently active but not recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Indianapolis, Indiana, 46202, United States
Research Site

Garden City, New York, 11530, United States
Research Site

Durham, North Carolina, 27705, United States
Research Site

Columbus, Ohio, 43203, United States
Research Site

Nashville, Tennessee, 37212, United States
Research Site

Ciudad de Buenos Aires, C1199, Argentina
Research Site

Clayton, 3168, Australia
Research Site

Herston, 4029, Australia
Research Site

Parkville, 3052, Australia
Research Site

St Leonards, 2065, Australia
Research Site

Belo Horizonte, 30130-100, Brazil
Research Site

Brasília, 71625-009, Brazil
Research Site

Recife, 50740-465, Brazil
Research Site

Salvador, 40050-410, Brazil
Research Site

São Paulo, 01409-902, Brazil
Research Site

São Paulo, 05403-900, Brazil
Research Site

Calgary, Alberta, T2E 7Z4, Canada
Research Site

Edmonton, Alberta, T6G 2H7, Canada
Research Site

Winnepeg, Manitoba, R3E 3P4, Canada
Research Site

Oakville, Ontario, L6M 1M1, Canada
Research Site

Trois-Rivières, Quebec, G9A 4P3, Canada
Research Site

Beijing, 100039, China
Research Site

Beijing, 100730, China
Research Site

Changsha, 430033, China
Research Site

Chengdu, 610041, China
Research Site

Nanchang, 330006, China
Research Site

Qingdao, 266035, China
Research Site

Shanghai, 201306, China
Research Site

Shenzhen, 518053, China
Research Site

Paris, 75014, France
Research Site

Poitiers, 86000, France
Research Site

Bad Reichenhall, 83435, Germany
Research Site

Berlin, 10117, Germany
Research Site

Bonn, 53127, Germany
Research Site

Hamburg, 20251, Germany
Research Site

Würzburg, 97074, Germany
Research Site

Ashkelon, 7830604, Israel
Research Site

Ramat Gan, 52621, Israel
Research Site

Florence, 50139, Italy
Research Site

Milan, 20122, Italy
Research Site

Milan, 20132, Italy
Research Site

Padova, 35128, Italy
Research Site

Pisa, 56126, Italy
Research Site

San Giovanni Rotondo, 71013, Italy
Research Site

Verona, 37134, Italy
Research Site

Hiroshima, 734-8551, Japan
Research Site

Iizuka-shi, 820-8505, Japan
Research Site

Osaka, 545-8586, Japan
Research Site

Sapporo, 060-8648, Japan
Research Site

Yaizu-shi, 425-8505, Japan
Research Site

Lodz, 93-338, Poland
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 07061, South Korea
Research Site

Suwon, 16499, South Korea
Research Site

Barcelona, 08003, Spain
Research Site

Granada, 18016, Spain
Research Site

Madrid, 28046, Spain
Research Site

San Cristóbal de La Laguna, 38320, Spain
Research Site

Santander, 39008, Spain
Research Site

Vitoria-Gasteiz, 01009, Spain
Research Site

Taipei, 100, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Ankara, 06560, Turkey (Türkiye)
Research Site

Erzurum, 25240, Turkey (Türkiye)
Research Site

London, SW170QT, United Kingdom

Conditions

Explore the condition pages connected to this study.

HYPOPHOSPHATASIA